Literature DB >> 23031498

Immune interference in the setting of same-day administration of two similar inactivated alphavirus vaccines: eastern equine and western equine encephalitis.

Ronald B Reisler1, Paul H Gibbs, Denise K Danner, Ellen F Boudreau.   

Abstract

We compared the effect on primary vaccination plaque-reduction neutralization 80% titers (PRNT80) responses of same-day administration (at different injection sites) of two similar investigational inactivated alphavirus vaccines, eastern equine encephalitis (EEE) vaccine (TSI-GSD 104) and western equine encephalitis (WEE) vaccine (TSI-GSD 210) to separate administration. Overall, primary response rate for EEE vaccine was 524/796 (66%) and overall primary response rate for WEE vaccine was 291/695 (42%). EEE vaccine same-day administration yielded a 59% response rate and a responder geometric mean titer (GMT)=89 while separate administration yielded a response rate of 69% and a responder GMT=119. WEE vaccine same-day administration yielded a 30% response rate and a responder GMT=53 while separate administration yielded a response rate of 54% and a responder GMT=79. EEE response rates for same-day administration (group A) vs. non-same-day administration (group B) were significantly affected by gender. A logistic regression model predicting response to EEE comparing group B to group A for females yielded an OR=4.10 (95% CL 1.97-8.55; p=.0002) and for males yielded an OR=1.25 (95% CL 0.76-2.07; p=.3768). WEE response rates for same-day administration vs. non-same-day administration were independent of gender. A logistic regression model predicting response to WEE comparing group B to group A yielded an OR=2.14 (95% CL 1.22-3.73; p=.0077). We report immune interference occurring with same-day administration of two completely separate formalin inactivated viral vaccines in humans. These findings combined with the findings of others regarding immune interference would argue for a renewed emphasis on studying the immunological mechanisms of induction of inactivated viral vaccine protection.
Copyright © 2012. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23031498     DOI: 10.1016/j.vaccine.2012.09.049

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  16 in total

1.  Recombinant Isfahan Virus and Vesicular Stomatitis Virus Vaccine Vectors Provide Durable, Multivalent, Single-Dose Protection against Lethal Alphavirus Challenge.

Authors:  Farooq Nasar; Demetrius Matassov; Robert L Seymour; Theresa Latham; Rodion V Gorchakov; Rebecca M Nowak; Grace Leal; Stefan Hamm; John H Eldridge; Robert B Tesh; David K Clarke; Scott C Weaver
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

2.  Venezuelan and western equine encephalitis virus E1 liposome antigen nucleic acid complexes protect mice from lethal challenge with multiple alphaviruses.

Authors:  Amber B Rico; Aaron T Phillips; Tony Schountz; Donald L Jarvis; Ronald B Tjalkens; Ann M Powers; Ken E Olson
Journal:  Virology       Date:  2016-09-12       Impact factor: 3.616

3.  Novel Insect-Specific Eilat Virus-Based Chimeric Vaccine Candidates Provide Durable, Mono- and Multivalent, Single-Dose Protection against Lethal Alphavirus Challenge.

Authors:  Jesse H Erasmus; Robert L Seymour; Jason T Kaelber; Dal Y Kim; Grace Leal; Michael B Sherman; Ilya Frolov; Wah Chiu; Scott C Weaver; Farooq Nasar
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

4.  Outflanking immunodominance to target subdominant broadly neutralizing epitopes.

Authors:  Davide Angeletti; Ivan Kosik; Jefferson J S Santos; William T Yewdell; Carolyn M Boudreau; Vamsee V A Mallajosyula; Madeleine C Mankowski; Michael Chambers; Madhu Prabhakaran; Heather D Hickman; Adrian B McDermott; Galit Alter; Jayanta Chaudhuri; Jonathan W Yewdell
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-18       Impact factor: 11.205

5.  Combined alphavirus replicon particle vaccine induces durable and cross-protective immune responses against equine encephalitis viruses.

Authors:  Douglas S Reed; Pamela J Glass; Russell R Bakken; James F Barth; Cathleen M Lind; Luis da Silva; Mary Kate Hart; Jonathan Rayner; Kim Alterson; Max Custer; Jeanne Dudek; Gary Owens; Kurt I Kamrud; Michael D Parker; Jonathan Smith
Journal:  J Virol       Date:  2014-08-13       Impact factor: 5.103

6.  Current strategic thinking for the development of a trivalent alphavirus vaccine for human use.

Authors:  Daniel N Wolfe; D Gray Heppner; Shea N Gardner; Crystal Jaing; Lesley C Dupuy; Connie S Schmaljohn; Kevin Carlton
Journal:  Am J Trop Med Hyg       Date:  2014-05-19       Impact factor: 2.345

7.  Liposome-antigen-nucleic acid complexes protect mice from lethal challenge with western and eastern equine encephalitis viruses.

Authors:  Aaron T Phillips; Tony Schountz; Ann M Toth; Amber B Rico; Donald L Jarvis; Ann M Powers; Ken E Olson
Journal:  J Virol       Date:  2013-11-20       Impact factor: 5.103

8.  Combination of two candidate subunit vaccine antigens elicits protective immunity to ricin and anthrax toxin in mice.

Authors:  David J Vance; Yinghui Rong; Robert N Brey; Nicholas J Mantis
Journal:  Vaccine       Date:  2014-12-02       Impact factor: 3.641

Review 9.  SARS-CoV-2 Liability: The Hidden Mystery Behind Its Presentation in Children.

Authors:  Reza Jafarzadeh Esfehani; Mohammad Hassan Aelami; Afsaneh Rezaei Kalat; Saman Soleimanpour; Zahra Pasdar; Majid Khazaei; Alireza Pasdar; Amir Avan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

10.  Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial.

Authors:  Emily E Coates; Srilatha Edupuganti; Grace L Chen; Myra Happe; Larisa Strom; Alicia Widge; Maria Burgos Florez; Josephine H Cox; Ingelise Gordon; Sarah Plummer; Abidemi Ola; Galina Yamshchikov; Charla Andrews; Sharon Curate-Ingram; Patricia Morgan; Shashi Nagar; Matthew H Collins; Amy Bray; Thuy Nguyen; Judy Stein; Christopher L Case; Florence Kaltovich; Diane Wycuff; C Jason Liang; Kevin Carlton; Sandra Vazquez; John R Mascola; Julie E Ledgerwood
Journal:  Lancet Infect Dis       Date:  2022-05-11       Impact factor: 71.421

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.